Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Inyta

- PMLiVE

Pfizer’s RSV vaccine candidate for older adults backed by FDA Advisory Committee

RSV infections in older adults account for 60,000 to 160,000 hospitalisations each year in the US

- PMLiVE

Pfizer’s maternal RSV vaccine candidate accepted for FDA priority review

Globally, RSV infections cause over 100,000 child deaths annually

- PMLiVE

Pfizer’s Talzenna combination shows promise in phase 3 prostate cancer study

10-20% of patients develop metastatic prostate cancer within five to seven years of diagnosis

- PMLiVE

AstraZeneca’s Evusheld not recommended by NICE for COVID-19 prevention

The agency said there is not enough evidence of the drug’s effectiveness against current variants

- PMLiVE

Pfizer/BioNTech initiate study of first mRNA shingles vaccine candidates

Around 95% of people over the age of 50 have been exposed to the virus that causes shingles

Case study: How we iteratively tested and refined payer value messages

Find out how we helped our client to enrich their understanding of the value message trade-off choices and preferences made by payers

Research Partnership

- PMLiVE

Pfizer expands low-cost medicine and vaccine programme to include off-patent products

The company will now offer 500 products to 45 lower-income countries on a not-for-profit basis

- PMLiVE

FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine

Preliminary data showed a possible link between the updated vaccine and a higher risk of stroke

- PMLiVE

Moderna and CytomX to partner in deal worth up to 1.2bn

The companies plan to develop mRNA-based therapies for a wide range of diseases

- PMLiVE

Pfizer and Gero collaborate on fibrotic disease research

The companies will use data to identify genes and pathways linked to fibrotic diseases

- PMLiVE

Pfizer announces positive phase 3 results for haemophilia B gene therapy

A one-off, intravenous dose of the therapy candidate reduced bleeding by 71%

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu recommended by NICE for advanced breast cancer

The treatment has been recommended for use within a managed access arrangement

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links